Importance of idiopathic pulmonary fibrosis staging for clinical trial endpoints
Am J Respir Crit Care Med
.
2013 Jun 1;187(11):1271.
doi: 10.1164/rccm.201208-1555LE.
Authors
Oisin J O'Connell
,
Peter Riddell
,
Jim J Egan
PMID:
23725620
DOI:
10.1164/rccm.201208-1555LE
No abstract available
Publication types
Letter
Comment
MeSH terms
Clinical Trials, Phase III as Topic / methods*
Endpoint Determination / methods*
Humans
Idiopathic Pulmonary Fibrosis / drug therapy*
Respiratory System Agents / therapeutic use*
Substances
Respiratory System Agents